Rigel Pharmaceuticals Releases Preliminary Q4 2025 Results and 2026 Outlook
Rigel Pharmaceuticals announced preliminary Q4 2025 revenue of $69.8 million and full-year revenue of $294.3 million, with a 2026 projection of $275-$290 million. Analyst Joseph Pantginis maintained a Buy rating.